drugset
drugset / Trial / NCT03387215

Randomized, Double-Blind, Placebo-Controlled, Safety and Tolerability Study of ITI-214 in Patients With Heart Failure

NCT03387215 ↗

Phase 1/2 Completed 36 enrolled Intra-Cellular Therapies, Inc.
RandomizedSequentialQuadruple-blindTreatment

Summary

This is a Phase I/II randomized, double-blind, placebo-controlled, single rising dose study in patients with systolic heart failure to evaluate the safety and tolerability of ITI-214.

Timeline

Start
2018-07-10
Primary completion
2020-03-16
Completion
2020-03-16

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Lenrispodun Small molecule 10 mg Oral
Subject Lenrispodun Small molecule 30 mg Oral
Subject Lenrispodun Small molecule 75 mg Oral
Subject Lenrispodun Small molecule 150 mg Oral

Indications

systolic heart failure